RUTH MOLLET: Open Payments
NPI 1992246516 · SPOKANE, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,996 in 84 payments from 15 companies in 2025. Trend: 2023 $1,275 · 2024 $1,963 · 2025 $1,996
Food & beverage: $1,996
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 30 | $534 |
| Lilly USA, LLC | 7 | $385 |
| Janssen Biotech, Inc. | 12 | $205 |
| Madrigal Pharmaceuticals | 3 | $160 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $133 |
| GENZYME CORPORATION | 4 | $105 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $97 |
| Aimmune Therapeutics, Inc. | 4 | $94 |
| Regeneron Healthcare Solutions, Inc. | 3 | $73 |
| Ardelyx, Inc. | 4 | $68 |
Products named: RINVOQ, OMVOH, TREMFYA, DUPIXENT, REZDIFFRA, XIFAXAN, ZENPEP, MAVYRET.
Industry payments across WA — which companies pay providers there.
